Grant: Discovery Grants Program - Individual
University of Ottawa
$32,000.00
Clearance of membrane aggregates in mutant ALS8
FY 2010-11
Summary
) A single amino acid mutation, proline residue at position 56 substituted by serine (P56S), in a previously identified gene named VAPB causes late-onset, autosomal dominant form of Amyotrophic Lateral Sclerosis (ALS8). VAPB is a protein anchored to the membrane of the endoplasmic reticulum (ER), a cellular network of membranes that is the entry point for secretory and membrane proteins. The ER has a quality control feature to ensure that proteins are correctly folded before they can leave the ER en route to their final destinations. Expression of VAPB-P56S disrupts this quality control feature and slows down the exit of proteins from the ER. This creates a protein traffic jam that eventually causes aggregation and stress to the ER. Cells have an adaptive process known as the unfolded protein response or UPR to counteract ER stress. UPR is designed to reduce the effect of increased protein load by (1) expanding the membrane capacity of the ER to accommodate the increased load; (2) by promoting the degradation of unfolded proteins; and (3) by temporarily shutting down new protein synthesis to reduce the amount of proteins entering the ER. However, if these countermeasures fail to relieve the stress, genes leading to cell death are then activated to eliminate the affected cell. We have discovered that a short peptide sequence known as the FFAT motif (two phenylalanines in an acidic tract) can change the activity of VAPB. It rescued the defect caused by the P56S mutation, so that proteins can now effectively leave the ER thereby relieving stress to the ER. This study will determine how the ALS8 mutation changes the UPR, and how FFAT resolves the ER membrane aggregates. It will explore whether this approach can be applied to other aggregate-prone neurodegenerative diseases such as Huntington's and Parkinson's Diseases.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
183973-2009
Name nom
Ngsee, Johnny
Department département
Cellular and Molecular Medicine
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2009
Award amount
32000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
32
Committee name en
Cell Biology
Committee name fr
Biologie cellulaire
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5103
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell membranes
Research subject fr
Membranes cellulaires
Partie
2
Nb partie
5
Application title
Clearance of membrane aggregates in mutant ALS8
Keyword
NSERC
Application summary
) A single amino acid mutation, proline residue at position 56 substituted by serine (P56S), in a previously identified gene named VAPB causes late-onset, autosomal dominant form of Amyotrophic Lateral Sclerosis (ALS8). VAPB is a protein anchored to the membrane of the endoplasmic reticulum (ER), a cellular network of membranes that is the entry point for secretory and membrane proteins. The ER has a quality control feature to ensure that proteins are correctly folded before they can leave the ER en route to their final destinations. Expression of VAPB-P56S disrupts this quality control feature and slows down the exit of proteins from the ER. This creates a protein traffic jam that eventually causes aggregation and stress to the ER. Cells have an adaptive process known as the unfolded protein response or UPR to counteract ER stress. UPR is designed to reduce the effect of increased protein load by (1) expanding the membrane capacity of the ER to accommodate the increased load; (2) by promoting the degradation of unfolded proteins; and (3) by temporarily shutting down new protein synthesis to reduce the amount of proteins entering the ER. However, if these countermeasures fail to relieve the stress, genes leading to cell death are then activated to eliminate the affected cell. We have discovered that a short peptide sequence known as the FFAT motif (two phenylalanines in an acidic tract) can change the activity of VAPB. It rescued the defect caused by the P56S mutation, so that proteins can now effectively leave the ER thereby relieving stress to the ER. This study will determine how the ALS8 mutation changes the UPR, and how FFAT resolves the ER membrane aggregates. It will explore whether this approach can be applied to other aggregate-prone neurodegenerative diseases such as Huntington's and Parkinson's Diseases.